Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 1:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 176 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Viaject 7 Clear all
Completed Not applicable Interventional Results available

Safety and Feasibility Testing of a Smaller Network Version of AIDANET

NCT06633965
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
AIDANET
Device
Lead sponsor
Marc Breton
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 19, 2026, 1:40 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Pulses Consumption and Its Role in Managing Systemic Inflammation, Insulin Sensitivity and Gut Microbiome in Human

NCT04267705
View directory record Official record
Conditions
Insulin Sensitivity, Overweight or Obesity, Inflammatory Response
Interventions
Control, Black bean, Chickpea
Other
Lead sponsor
Clinical Nutrition Research Center, Illinois Institute of Technology
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 19, 2026, 1:40 PM EDT
Completed No phase listed Observational

MiniMed Fit Payload Wear Study

NCT07408141
View directory record Official record
Conditions
Diabetes (Insulin-requiring, Type 1 or Type 2)
Interventions
MiniMed Fit Payload adhesive components
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
4
States / cities
Chula Vista, California • Escondido, California • Long Island City, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 19, 2026, 1:40 PM EDT
Completed Phase 1 Interventional Results available

A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors

NCT00816361
View directory record Official record
Conditions
Cancer
Interventions
MEDI-573
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
6
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Oct 19, 2026, 1:40 PM EDT
Recruiting Phase 1 Interventional

Effect of Insulin Lowering on Lipogenesis

NCT07403604
View directory record Official record
Conditions
Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease, Prediabetic State, Obesity
Interventions
Placebo, Diazoxide Oral Suspension, 2 mg per kg per dose, Deuterated water (2H2O/D2O), 70%, Insulin Suppression Test (IST)
Drug · Diagnostic Test
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 19, 2026, 1:40 PM EDT
Completed No phase listed Observational

Pharmacodynamics of CNP During Growth Hormone Treatment

NCT01504802
View directory record Official record
Conditions
Pituitary Dwarfism, Idiopathic Short Stature
Interventions
Not listed
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
3 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Los Angeles, California • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 2, 2014 · Synced Oct 19, 2026, 1:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Changes in Insulin Sensitivity After Weight Loss

NCT00627484
View directory record Official record
Conditions
Obesity, Type 2 Diabetes Mellitus, Insulin Resistance
Interventions
Gastric bypass, Gastric banding, Sleeve gastrectomy, Very low calorie diet
Procedure · Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 75 Years
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Oct 19, 2026, 1:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Low and Moderate Fat Diets on Lipids, Inflammation and Vascular Reactivity in the Metabolic Syndrome

NCT00362908
View directory record Official record
Conditions
Metabolic Syndrome X, Dyslipidemias
Interventions
Moderate Fat and Moderate Carbohydrate Diet, Low Fat and High Carbohydrate Diet
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
30 Years to 75 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 28, 2010 · Synced Oct 19, 2026, 1:40 PM EDT
Completed Phase 4 Interventional Results available

Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes

NCT02408120
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin glargine, Insulin aspart, Supplemental insulin aspart
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 19, 2026, 1:40 PM EDT
Recruiting Phase 3 Interventional

AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications

NCT07797335
View directory record Official record
Conditions
Type 2 Diabetes, Cardiovascular Risk
Interventions
Zenagamtide, Insulin glargine U-100
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
45 Years and older
Enrollment
1,778 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
109
States / cities
Birmingham, Alabama • Fairhope, Alabama • Montgomery, Alabama + 91 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 19, 2026, 1:40 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Breaking up Prolonged Sedentary Behavior to Improve Cardiometabolic Health

NCT05353322
View directory record Official record
Conditions
Sedentary Behavior, Cardiometabolic Risk Factors, Blood Pressure, Glucose
Interventions
Sedentary Break (Walking) Condition, Sitting (Control) Condition, Controlled Diet
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 19, 2026, 1:40 PM EDT
Completed Not applicable Interventional

mHealth Insulin Titration and Management (iSage)

NCT03704103
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
iSage
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
21 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 19, 2026, 1:40 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF)

NCT03608163
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Hypoglycemia, Hypoglycemia Unawareness
Interventions
Naloxone, Diazoxide, Placebo (for Naloxone), Placebo (for Diazoxide)
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
21 Years to 55 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 19, 2026, 1:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Amount and Type of Dietary Carbohydrates on Risk for Cardiovascular Heart Disease and Diabetes

NCT00608049
View directory record Official record
Conditions
Overweight, Cardiovascular Diseases
Interventions
High carbohydrate and low glycemic index (GI) diet, Low carbohydrate and low GI diet, High carbohydrate and high GI diet, Low carbohydrate and high GI diet
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
30 Years and older
Enrollment
189 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 19, 2026, 1:40 PM EDT
Completed Phase 3 Interventional

Islet Transplantation in Type 1 Diabetes

NCT00434811
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Allogeneic Pancreatic Islet Cells, Antithymocyte Globulin, Sirolimus, Tacrolimus, Etanercept, Islet Transplantation, Basiliximab
Biological · Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
7
States / cities
San Francisco, California • Miami, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Oct 19, 2026, 1:40 PM EDT
Completed No phase listed Observational

Effectiveness and Safety Study of the Next-Generation DexCom™ SEVEN® Continuous Glucose Monitoring System

NCT00722241
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Not listed
Lead sponsor
DexCom, Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
3
States / cities
Concord, California • Escondido, California • Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2008 · Synced Oct 19, 2026, 1:40 PM EDT
Completed Early Phase 1 Interventional

Evaluation of the Molecular Effects of Metformin on the Endometrium in Patients With Endometrial Cancer

NCT01205672
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Metformin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2017 · Synced Oct 19, 2026, 1:40 PM EDT
Completed Phase 3 Interventional

Efficacy of Islet After Kidney Transplantation

NCT00468117
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Islet transplantation, Antithymocyte Globulin, Daclizumab or Basiliximab, Etanercept, Allogenic human purified pancreatic islets
Procedure · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 68 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
9
States / cities
San Francisco, California • Miami, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2017 · Synced Oct 19, 2026, 1:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of a Calorie Restricted, Very Low Fat Plant-based Diet and Multi-component Exercise Program on Metabolic Health

NCT02706288
View directory record Official record
Conditions
Obesity, Insulin Resistance
Interventions
Weight loss with very low fat plant-based diet and regular exercise
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Oct 19, 2026, 1:40 PM EDT
Completed Phase 2Phase 3 Interventional Results available

The Insulin-Only Bionic Pancreas Bridging Study

NCT03565666
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog, iLet Bionic Pancreas insulin-only configuration with Fiasp, Usual care
Device · Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Palo Alto, California • Aurora, Colorado • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 19, 2026, 1:40 PM EDT
Completed Phase 2 Interventional Results available

Cardiac Surgery Neuroprotection Study in Elders

NCT01561378
View directory record Official record
Conditions
Post-operative Cognitive Decline, Post-operative Delirium
Interventions
Aspart insulin, Normal saline, Intranasal mucosal atomizer device
Drug · Device
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
65 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Oct 19, 2026, 1:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dose-Finding Study of Intranasal Insulin in Healthy Participants Insulin in Healthy Participants

NCT05062785
View directory record Official record
Conditions
Out-Of-Hospital Cardiac Arrest, Healthy
Interventions
Intranasal insulin
Drug
Lead sponsor
Robert Silbergleit
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 19, 2026, 1:40 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women

NCT01475513
View directory record Official record
Conditions
Insulin Sensitivity, Cardiovascular Risk, Perimenopausal Disorder
Interventions
Ortho Cyclen®
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Oct 19, 2026, 1:40 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Soluble Epoxide Hydrolase Inhibition and Insulin Resistance

NCT03486223
View directory record Official record
Conditions
Diabetes Mellitus, Endocrine System Diseases, Glucose Metabolism Disorders, PreDiabetes, Obesity
Interventions
GSK2256294, Placebo oral capsule
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
21 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 19, 2026, 1:40 PM EDT